argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline

argenx announced a $2.2 billion cash acquisition of Forte Biosciences at $77 per share, a significant M&A event in the immunology space. The deal adds FB102, a first-in-class anti-CD122 antibody, to argenx's existing immunology pipeline, representing strategic portfolio expansion in a high-value therapeutic area where differentiated mechanisms command premium valuations.

The transaction signals argenx's confidence in expanding its immunology franchise through external innovation. FB102's first-in-class status suggests limited competitive overlap and potential for commanding pricing power once approved, a critical factor for biotech investors evaluating long-term revenue potential and return on acquisition capital.

For FBRX shareholders, the $77/share offer provides certainty at a defined valuation, eliminating binary development risk. For ARGX, the deal represents capital deployment into a validated therapeutic area but increases pipeline execution risk and near-term cash burn, offsetting by strategic asset strengthening and revenue runway extension.

Sector implication: This acquisition reflects robust M&A activity in Health Care immunology, where specialized antibody platforms command premium acquisition multiples. The deal supports biotech sector sentiment amid ongoing consolidation and validates market appetite for first-in-class immunotherapies despite broader market volatility.